Perioperative chemotherapy in muscle-invasive bladder cancer: overview and the unmet clinical need for alternative adjuvant therapy as studied in the MAGNOLIA trial.

[1]  Steven L. Chang,et al.  Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. , 2014, European urology.

[2]  J. Bellmunt,et al.  New therapeutic challenges in advanced bladder cancer. , 2012, Seminars in oncology.

[3]  P. Mulders,et al.  Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire. , 2012, European urology.

[4]  J. Gore,et al.  Mortality increases when radical cystectomy is delayed more than 12 weeks , 2009, Cancer.

[5]  Yair Lotan,et al.  Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. , 2006, The Journal of urology.

[6]  A. Simpson,et al.  Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[7]  C. Vale.  Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .

[8]  R. Hautmann,et al.  Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. , 2005, The Journal of urology.

[9]  E. Yano,et al.  Urologic diseases in America Project: analytical methods and principal findings. , 2005, The Journal of urology.

[10]  C. Sternberg,et al.  Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. , 2003, Critical reviews in oncology/hematology.

[11]  L. Collette,et al.  Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. , 2006, European journal of cancer.